Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Leukemia

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/leu.2012.134PMID 22699418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discontinuation of Imatinib in Patients with CML and Sustained Complete Molecular Response (CMR) for Over 2 Years in the Japanese Population – An Interim Analysis of KEIO STIM Study,

  2011cited by this paper
• CML: live long and prosper.

  2011cited by this paper
• Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

  2011cited by this paper
• Discontinuation of Dasatinib or Nilotinib in Chronic Myeloid Leukemia (CML) Patients (pts) with Stable Undetectable Bcr-Abl Transcripts: Results From the French CML Group (FILMC)

  2011cited by this paper
• Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study

  2011cited by this paper
• Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

  2011cited by this paper
• A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

  2011cited by this paper
• Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

  2010cited by this paper
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

  2010cited by this paper
• Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

  2010cited by this paper
• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2010cited by this paper
• Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

  2009cited by this paper
• Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

  2009cited by this paper
• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2009cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• Analysis of the complementary determining region III of the immunoglobulin heavy chain locus in acute lymphoblastic leukemia in Chilean children.

  1996cited by this paper

• The Comparison of First-Line Dasatinib Therapy 70 mg/day Versus 100 mg/day in Newly Diagnosed Patients with Chronic Myeloid Leukemia in the Chronic Phase: a Prospective, Randomized, Multicenter 1-year Clinical Study

  2026cites this paper
• Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow

  2026cites this paper
• Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.

  2025cites this paper
• Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa

  2025cites this paper
• Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database

  2025cites this paper
• Assessment of the risk of vascular adverse events by Doppler ultrasound in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: a case control study

  2025cites this paper
• Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases

  2025influential citation
• Preventive, Personalized, and Precision Medicine and Biomarkers for Breast Cancer Diagnosis: Artificial Intelligence Framework

  2025cites this paper
• [Guideline for the diagnosis and treatment of chronic myeloid leukemia in China (2025)].

  2025cites this paper
• CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study

  2024cites this paper
• The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia

  2024cites this paper
• The Sirt1/Nrf2 pathway is a key factor for drug therapy in chemotherapy-induced cardiotoxicity: a Mini-Review

  2024cites this paper
• Engineering for Biomedical Sector: A Cross-Industry Approach for the Analysis of Molecular Patterns behind Endothelial Damage Related to Leukemia Therapy

  2024cites this paper
• BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

  2024cites this paper
• Outcomes of Dose Escalation of Imatinib in Chronic Myeloid Leukemia Patients: A Retrospective Analysis From an Indian University Teaching Hospital

  2024cites this paper
• Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management

  2023cites this paper
• Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13‐Mediated Stabilization of Bcl‐XL

  2023cites this paper
• Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies

  2023cites this paper
• Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects

  2023cites this paper
• Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

  2023cites this paper
• Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study

  2023cites this paper
• A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia

  2023cites this paper
• Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort

  2023cites this paper
• Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

  2022cites this paper
• Inequality in Drug Utilization among Chronic Myeloid Leukaemia Patients in Malaysia: A Cost-Utility Analysis

  2022cites this paper
• The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.

  2022cites this paper
• CD26/DPP-4 in Chronic Myeloid Leukemia

  2022cites this paper
• Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory

  2022cites this paper
• Tyrosine kinase inhibitors reduce myeloid-derived suppressor cells in patients with chronic myeloid leukemia with better outcome

  2022cites this paper
• Safety and Tolerability of Nilotinib in Patients with Chronic Myeloid Leukemia during Routine Clinical Practice: Results from the ERASER Study from Greece

  2022cites this paper
• A New Paradigm of Cardio-Hematological Monitoring in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors

  2022cites this paper
• Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow-up of the GIMEMA CML 0307 study

  2022cites this paper
• Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials

  2022cites this paper
• Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review

  2022influential citation
• hyperlipidemia-post-initiation-of-nilotinib-among-chronic-myeloid-leukemia-patients-in-a-tertiary-hospital-of-malaysia

  2022cites this paper
• Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment.

  2022cites this paper
• Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

  2022cites this paper
• NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan

  2022influential citation
• Plexiform neurofibroma: shedding light on the investigational agents in clinical trials

  2021cites this paper
• Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors

  2021cites this paper
• Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib

  2021cites this paper
• Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells

  2021cites this paper
• A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience

  2021cites this paper
• Author's Reply.

  2021cites this paper
• Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.

  2021cites this paper
• Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China

  2021cites this paper
• Dasatinib-Induced Nephrotic Syndrome: A Case Report

  2021cites this paper
• The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia

  2021cites this paper
• Tyrosine kinase inhibitor and vascular adverse events in chronic myeloid leukemia patients: a population-based, propensity score-matched cohort study.

  2021cites this paper
• Arterial hypertension assessment in a population with chronic myeloid leukemia

  2021cites this paper
• Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment

  2021cites this paper
• Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia

  2021cites this paper
• Molecular response in long-term monitoring of patients with chronic myelogenic leukemia (CML) on nilotinib therapy

  2021cites this paper
• Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.

  2021cites this paper
• Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

  2021cites this paper
• Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

  2021cites this paper
• Management of Adverse Events Associated With Tyrosine Kinase Inhibitor Use in Adult Patients With Chronic Myeloid Leukemia in Chronic Phase: An Advanced Practice Perspective

  2021influential citation
• Quality of life of patients with leukemia undergoing chemotherapy

  2021cites this paper
• Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia

  2021cites this paper
• A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia

  2021cites this paper
• Long‐term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)

  2020cites this paper
• Case Report of acute myeloid leukemia with “WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19” developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy

  2020cites this paper
• Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

  2020cites this paper
• ATVB IN FOCUS: Peripheral Artery Disease

  2020cites this paper
• Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective

  2020influential citation
• Leucémies chroniques

  2020cites this paper
• Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis

  2020cites this paper
• Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia

  2020cites this paper
• Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.

  2020cites this paper
• [The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)].

  2020cites this paper
• A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

  2020cites this paper
• Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies

  2020cites this paper
• Peripheral Artery Disease and Stroke

  2020cites this paper
• First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.

  2020cites this paper
• Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors

  2020cites this paper
• Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

  2020cites this paper
• Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring

  2020cites this paper
• A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia

  2020cites this paper
• Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients

  2020cites this paper
• Chronic Myeloid Leukemia in India: A Review

  2020cites this paper
• Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy.

  2019cites this paper
• Treatment-free remission in chronic myeloid leukemia.

  2019cites this paper
• Aortic wall stiffness as a side-effect of anti-cancer medication

  2019cites this paper
• Observation of Imatinib and Nilotinib in the Treatment of Chronic Myeloid Leukemia

  2019cites this paper
• Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia.

  2019cites this paper
• Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.

  2019cites this paper
• The efficacy of generic imatinib in patients with chronic myeloid leukemia - a single centre experience

  2019cites this paper
• ABC Transporter-Mediated Multidrug-Resistant Cancer.

  2019cites this paper
• 尼洛替尼暴露对女性慢性髓性白血病患者妊娠结局的影响

  2019cites this paper
• Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities

  2019cites this paper
• Continuous cytostatic effects of BCR-ABL tyrosine kinase inhibitors (TKIs) after washout in human leukemic K562 cells.

  2019cites this paper
• Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

  2019cites this paper
• Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis

  2019cites this paper
• Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells

  2019cites this paper
• Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors

  2019cites this paper
• Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening

  2019cites this paper
• Systematic Review and Meta-Analysis of New-Generation Tyrosine Kinase Inhibitors versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

  2019cites this paper
• Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

  2019cites this paper
• How I treat chronic myeloid leukemia in children and adolescents.

  2019cites this paper
• A Case of Severe, Nilotinib-Induced Liver Injury

  2019cites this paper